Emergent BioSolutions (NYSE:EBS) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Emergent BioSolutions (NYSE:EBS) in a research note published on Tuesday,Benzinga reports. The firm currently has a $15.00 price objective on the biopharmaceutical company’s stock.

EBS has been the subject of a number of other research reports. Benchmark raised their price objective on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, November 7th. StockNews.com upgraded shares of Emergent BioSolutions from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th.

Emergent BioSolutions Stock Performance

NYSE EBS opened at $11.45 on Tuesday. The firm’s fifty day moving average price is $9.27 and its two-hundred day moving average price is $9.27. The stock has a market cap of $620.09 million, a PE ratio of -2.79 and a beta of 1.60. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. Emergent BioSolutions has a fifty-two week low of $1.42 and a fifty-two week high of $15.10.

Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $1.37 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.88. The business had revenue of $293.80 million for the quarter, compared to analyst estimates of $328.72 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. During the same quarter in the previous year, the company posted ($1.44) EPS. On average, equities analysts expect that Emergent BioSolutions will post -0.63 EPS for the current fiscal year.

Institutional Trading of Emergent BioSolutions

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EBS. American Century Companies Inc. lifted its position in shares of Emergent BioSolutions by 240.9% in the 2nd quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock worth $6,015,000 after purchasing an additional 623,201 shares during the period. Vanguard Personalized Indexing Management LLC bought a new position in Emergent BioSolutions during the second quarter worth $93,000. Hsbc Holdings PLC lifted its holdings in Emergent BioSolutions by 36.1% in the second quarter. Hsbc Holdings PLC now owns 87,679 shares of the biopharmaceutical company’s stock valued at $614,000 after buying an additional 23,250 shares during the period. XTX Topco Ltd boosted its position in Emergent BioSolutions by 218.0% during the second quarter. XTX Topco Ltd now owns 62,764 shares of the biopharmaceutical company’s stock valued at $428,000 after acquiring an additional 43,028 shares during the last quarter. Finally, Morse Asset Management Inc acquired a new stake in Emergent BioSolutions during the 2nd quarter worth about $97,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.